LENZ Therapeutics (LENZ)

• Market cap: $656M
• 1 day: 3.30%
• 5 days: 28.48%
• 1 month: 0.97%
• 3 months: 5.87%
• 6 months: -9.50%
• Year to date: -15.80%
• 1 year: 34.58%
• 5 years: -81.61%
• 10 years: -81.61%
• Sector: Healthcare
• Industry: Biotechnology

About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Employees: 42

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

167% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 9

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

29% more capital invested

Capital invested by funds: $445M [Q3] → $573M (+$128M) [Q4]

19% more funds holding

Funds holding: 78 [Q3] → 93 (+15) [Q4]

4.1% more ownership

Funds ownership: 68.13% [Q3] → 72.23% (+4.1%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 26% upside
• Avg. target: $43 79% upside
• High target: $51 114% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 16 / 68 met price target	26% upside $30	Buy Reiterated	16 Apr 2025
Piper Sandler Biren Amin 20% 1-year accuracy 5 / 25 met price target	114% upside $51	Overweight Maintained	14 Apr 2025
Citigroup Yigal Nochomovitz 12% 1-year accuracy 5 / 41 met price target	97% upside $47	Buy Maintained	20 Mar 2025